The study’s limitations include its retrospective nature, limited case number, exclusion of five of the residual genes defined by the IPSS-M model, unavailability of TP53 copy-neutral loss of heterozygosity, and heterogeneity in treatment regimens, though most high-risk MDS patients received hypomethylating agents or transplantation. Here, TP53 is linked to myelodysplastic syndrome.